NCT04747678Unknown不适用
Tolerability and Adverse Effects of Using Multiple Doses of Ivermectin in Egypt During Covid 19 Pandemic
适应症
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- all adverse effects will be collected from people used Ivermectin in between September 2020 to December 2020
研究概览
简要总结
retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt
详细描述
ivermectin was used in Egypt during the pandemic of covid-19 and it was registered in the MOH protocol that has been published in November 2020 the study will document the adverse effects of many patients used ivermectin as aprophylaxis and as a treatment with multiple dose regimens
研究设计
- 研究类型
- Observational
- 观察模型
- Case Crossover
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 16 Years 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •all people used ivermectin as a treatment or as a prophylactic in covid 19 pandemic in egypt with explained dose
排除标准
- 未提供
结局指标
主要结局
all adverse effects will be collected from people used Ivermectin in between September 2020 to December 2020
时间窗: the data will be collected from February 2021 to march 2021
all data will be collected from retrospective manner as a retrospective study
次要结局
- all data will be arranged according to time and dose manner(February to match 2021)
研究者
ahmed mohamed esmat fahim mansour
Principal Investigator
Menoufia University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741HealthyNCT01068028Orion Corporation, Orion Pharma49
已完成
1 期
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate AsthmaAsthmaNCT01370317Merck Sharp & Dohme LLC27
进行中（未招募）
2 期
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)Geographic Atrophy of the MaculaMacular DegenerationNCT05839041Aviceda Therapeutics, Inc.300
终止
1 期
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsAlzheimer's DiseaseNCT02220738AbbVie19
已完成
1 期
A Multiple Dose Study of MK-3614 (MK-3614-002)HypertensionNCT01033643Merck Sharp & Dohme LLC30